StockData
Altimmune, Inc. logo

Altimmune, Inc. (ALT) stock

ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$1.53−0.03 (-1.92%)

Close on Nov 17, 2026Market cap $297.61MP/E –Yield –

Altimmune operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Altimmune's operating cash flow for the twelve months ending Jun 30, 2026 was -$76.51M. For fiscal 2025 it was -$67.54M. The highest annual figure on record is -$2.32M in fiscal 2012.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$67.54M–
FY2024Dec 31, 2024-$79.85M–
FY2023Dec 31, 2023-$75.81M–
FY2022Dec 31, 2022-$62.59M–
FY2021Dec 31, 2021-$78.24M–
FY2020Dec 31, 2020-$34.31M–
FY2019Dec 31, 2019-$9.60M–
FY2018Dec 31, 2018-$9.39M–
FY2017Dec 31, 2017-$20.21M–
FY2016Dec 31, 2016-$6.35M–
FY2015Dec 31, 2015-$3.22M–
FY2014Dec 31, 2014-$8.47M–
FY2013Dec 31, 2013-$7.17M–
FY2012Dec 31, 2012-$2.32M–
FY2011Dec 31, 2011-$7.81M–
FY2010Dec 31, 2010-$14.86M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$24.22M–
Q1 FY2026Mar 31, 2026-$20.94M–
Q4 FY2025Dec 31, 2025-$19.45M–
Q3 FY2025Sep 30, 2025-$11.90M–
Q2 FY2025Jun 30, 2025-$19.35M–
Q1 FY2025Mar 31, 2025-$16.84M–
Q4 FY2024Dec 31, 2024-$18.27M–
Q3 FY2024Sep 30, 2024-$27.12M–
Q2 FY2024Jun 30, 2024-$18.11M–
Q1 FY2024Mar 31, 2024-$16.36M–
Q4 FY2023Dec 31, 2023-$16.53M–
Q3 FY2023Sep 30, 2023-$20.49M–
Q2 FY2023Jun 30, 2023-$19.38M–
Q1 FY2023Mar 31, 2023-$19.41M–
Q4 FY2022Dec 31, 2022-$17.31M–
Q3 FY2022Sep 30, 2022-$15.05M–
Q2 FY2022Jun 30, 2022-$16.70M–
Q1 FY2022Mar 31, 2022-$13.53M–
Q4 FY2021Dec 31, 2021-$21.97M–
Q3 FY2021Sep 30, 2021-$17.78M–
Q2 FY2021Jun 30, 2021-$18.93M–
Q1 FY2021Mar 31, 2021-$19.57M–
Q4 FY2020Dec 31, 2020-$13.28M–
Q3 FY2020Sep 30, 2020-$9.50M–
Q2 FY2020Jun 30, 2020-$7.17M–
Q1 FY2020Mar 31, 2020-$4.35M–
Q4 FY2019Dec 31, 2019-$2.00M–
Q3 FY2019Sep 30, 2019-$2.43M–
Q2 FY2019Jun 30, 2019-$3.06M-979.0%
Q1 FY2019Mar 31, 2019-$2.11M–
Q4 FY2018Dec 31, 2018-$5.16M–
Q3 FY2018Sep 30, 2018-$1.02M–
Q2 FY2018Jun 30, 2018$348.14K–
Q1 FY2018Mar 31, 2018-$3.56M–
Q4 FY2017Dec 31, 2017-$4.81M–
Q3 FY2017Sep 30, 2017-$4.26M–
Q2 FY2017Jun 30, 2017-$7.81M–
Q1 FY2017Mar 31, 2017-$3.34M–
Q4 FY2016Dec 31, 2016-$1.49M–
Q3 FY2016Sep 30, 2016-$1.89M–

More Altimmune figures

See a number that looks wrong?